英国生物库中罕见变异与血蛋白水平的相关性
Ryan S Dhindsa1, Oliver S Burren2, Benjamin B Sun3
1Centre for Genomics Research, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, US. ryan.dhindsa@astrazeneca.com.
Nature
|October 4, 2023
概括
这项研究揭示了罕见的遗传变异对血蛋白水平有重大影响,揭示了数千种新的关联,并突出了蛋白质基因组学在发现疾病机制和药物标方面的潜力.
科学领域:
- 人类基因组学和蛋白质组学
- 基因变异及其对蛋白质丰度的影响
背景情况:
- 之前的蛋白质基因组研究主要集中在常见的遗传变异上.
- 罕见变体在塑造血蛋白质中的作用在很大程度上尚未被探索.
研究的目的:
- 确定罕见的蛋白质编码变体与血蛋白质丰度之间的关联.
- 探索蛋白质基因组数据对于生物标志物发现和疾病机制的有用性.
主要方法:
- 对49,736名英国生物库个体进行了变异水平的外基因组广泛关联研究.
- 使用基因级崩分析来识别总基因与蛋白质的关联.
- 集成的蛋白质定量特征位点与蛋白质截断变体.
主要成果:
- 鉴定出5433个罕见的基因型与蛋白质关联,其中81%未在先前的全基因组关联研究中检测到.
- 发现了1962个基因与蛋白质的关联,其中蛋白质缩减变异主要与蛋白质水平下降有关.
- 发现了STAB1和STAB2的性作用,并揭示了克隆造血的蛋白质性后果.
结论:
- 罕见的遗传变异在确定血蛋白水平方面起着重要作用.
- 蛋白质基因组学为推进治疗发现和理解复杂疾病提供了宝贵的资源.
相关概念视频
Genome-wide Association Studies-GWAS
13.5K
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
13.5K
Drug Distribution: Plasma Protein Binding
5.7K
Drugs predominantly attach to plasma proteins, with only a small percentage remaining unbound. The unbound portion can be calculated as one minus the bound fraction. Acidic drugs form large, inactive complexes by reversibly binding to plasma albumin, which prevents them from diffusing across biological barriers. These drug-protein complexes act as reservoirs for the drugs. As the concentration of unbound drugs decreases, these complexes quickly dissociate to release the free drug, maintaining...
5.7K
Factors Affecting Protein-Drug Binding: Patient-Related Factors
67
Protein-drug binding, a pivotal aspect of pharmacokinetics, is subject to considerable variability influenced by an array of patient-related factors. The intricate interplay of age, individual differences, and pathological conditions significantly impact the binding dynamics and subsequent pharmacological effects.
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
67


